The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline.
CHICAGO --
The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. Patients were monitored using a scale that measures how they do in areas like memory, judgement, problem solving and personal care.
The initial results appear to be "quite robust" and will likely support regulatory approval, Mizuho Securities analyst Graig Suvannavejh said in a research note.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen stock increases as Alzheimer's drug shows promise in early results of studyEisai announced results from a global study of nearly 1,800 people with early-stage Alzheimer’s. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.
Read more »
Alzheimer's drug shows promise in early results of studyJapan's Eisai Co. said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. abc15
Read more »
Alzheimer’s drug shows promise in early results of studyThe drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.
Read more »
Alzheimer's Treatment Shows Promise in Early Results of Study, Drugmaker SaysBiogen and Japan’s Eisai Co. said early results showed that the treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo after 18 months of the infused treatment.
Read more »
Alzheimer’s drug results are promising – but not a major breakthroughTrial results for a new medicine to treat Alzheimer’s disease have been described as a historic breakthrough and an unequivocal win for those with Alzheimer’s – but these claims are overblown on the evidence so far, says clarewilsonmed
Read more »